Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239604 | 0.87 | EGFR (0.48) | EGFRALKKDR | |
| SCHEMBL23945054 | 0.86 | EGFR (0.40) | EGFRALKKDR | |
| SCHEMBL18239648 | 0.81 | EGFR (0.42) | EGFRMKNK2MKNK1 | |
| SCHEMBL19337257 | 0.78 | PIK3CA (0.41) | EGFRMKNK2ALKIGF1RPLK1 | |
| SCHEMBL18386752 | 0.78 | EGFR (0.39) | EGFRMKNK2MKNK1KDRPTK2 | |
| SCHEMBL17553836 | 0.78 | BMI1 (0.39) | EGFRPLK1KDRPTK2 | |
| SCHEMBL18387037 | 0.78 | EGFR (0.39) | EGFRMKNK2MKNK1KDRPTK2 | |
| SCHEMBL17683373 | 0.77 | KDR (0.39) | EGFRMKNK2ALKIGF1RMKNK1 | |
| SCHEMBL18239632 | 0.77 | EGFR (0.48) | EGFRALKKDR | |
| SCHEMBL19337165 | 0.77 | EGFR (0.40) | EGFRMKNK2ALKIGF1RMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885MKNK2 90/4885ALK 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.